Abstract:

Fibroblast  growth  factor  23  (FGF⁃23)  has  garnered  significant  attention  for  its  role  in  osteoporosis associated with  chronic  kidney  disease  (CKD).  Studies  have  shown  that  FGF⁃23  levels  are  markedly  elevated  in  CKD patients and  accelerate  the  progression  of  osteoporosis  through  complex  feedback  mechanisms.  This  review  provides  a comprehensive analysis of the  mechanisms  underlying  FGF⁃23􀆳s  involvement  in  CKD⁃related  osteoporosis  and  its  potential clinical applications, offering new perspectives and insights for the management of bone health in CKD patients.

Key words: fibroblast growth factor 23   , chronic kidney disease   , osteoporosis